Vident Advisory LLC Buys Shares of 15,040 QIAGEN N.V. $QGEN

Key Points

• Vident Advisory LLC has made a new investment in QIAGEN N.V., purchasing 15,040 shares valued at approximately $604,000 in the first quarter.
• Several hedge funds are modifying their holdings in QIAGEN, with 70% of the stock owned by institutional investors.
• QIAGEN reported its quarterly earnings meeting expectations with $0.60 EPS and a revenue of $533.54 million, marking a year-over-year revenue increase of 7.7%.

Vident Advisory LLC bought a new position in QIAGEN N.V. (NYSE:QGEN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,040 shares of the company's stock, valued at approximately $604,000.

Other institutional investors and hedge funds have also modified their holdings of the company. SVB Wealth LLC acquired a new position in shares of QIAGEN in the 1st quarter worth approximately $31,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of QIAGEN in the 1st quarter worth approximately $94,000. Tower Research Capital LLC TRC boosted its holdings in shares of QIAGEN by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after acquiring an additional 2,204 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after acquiring an additional 1,425 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of QIAGEN in the 1st quarter worth approximately $150,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on QGEN shares. Wall Street Zen downgraded QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. UBS Group boosted their target price on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Barclays assumed coverage on shares of QIAGEN in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. Cowen restated a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Finally, Bank of America boosted their price objective on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Three equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, QIAGEN presently has an average rating of "Hold" and a consensus target price of $49.69.

QIAGEN Trading Up 0.1%

QGEN stock traded up $0.05 during trading on Thursday, hitting $46.06. The company had a trading volume of 1,174,056 shares, compared to its average volume of 1,302,762. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $48.53 and a 200-day moving average price of $44.55. QIAGEN N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The stock has a market cap of $10.24 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 2.43 and a beta of 0.64.

QIAGEN (NYSE:QGEN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The business's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, analysts predict that QIAGEN N.V. will post 2.26 earnings per share for the current year.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.